Dr. Thomas Bump, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3545 W 95th St, Evergreen Park, IL 60805 Phone: 708-346-5562 Fax: 708-346-2059 |
Dr. Ali Raza Zaidi, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3545 W 95th St, Evergreen Park, IL 60805 Phone: 708-346-5562 |
Ibrahim Kassas, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3545 W 95th St, Evergreen Park, IL 60805 Phone: 708-346-5562 Fax: 708-346-2059 |
Joaquim Spadoni Barboza, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3545 W 95th St, Evergreen Park, IL 60805 Phone: 708-346-5562 |
Dr. Hussam Watti, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3545 W 95th St, Evergreen Park, IL 60805 Phone: 708-346-5562 |
Dr. William H Spear, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3545 W 95th St, Evergreen Park, IL 60805 Phone: 708-346-5562 |
Dr. Chadi Nouneh, M.D Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3545 W 95th St, Evergreen Park, IL 60805 Phone: 708-346-5562 |
News Archive
Professor Lynn Fraser told the 21st annual conference of the European Society of Human Reproduction and Embryology today (Wednesday), that her previous research had shown that certain chemicals known to mimic the female sex hormone, oestrogen, could individually affect the correct functioning of mouse sperm, but now her new research showed that when the chemicals were combined they had an even stronger effect.
Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis.
Arteriocyte, Inc., a leading clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, that develops proprietary stem cell and tissue engineering based therapies announced today the launch of its first commercially available Stem Cell Expansion System for research use.
The American Thoracic Society has issued the first-ever guidelines on the use of fractional exhaled nitric oxide (FENO) that address when to use FENO and how to interpret FENO levels in different clinical settings.
› Verified 1 days ago